<DOC>
	<DOCNO>NCT00115908</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Albuferon combination ribavirin interferon ( IFN ) alfa treatment-na√Øve subject chronic hepatitis C genotype 1 . The study randomize subject 1 4 treatment group include 3 different Albuferon group active control group , peginterferon alfa-2a ( PEGASYS , PEG-IFNalfa-2a ) . All subject also receive oral daily ribavirin .</brief_summary>
	<brief_title>A Study Albuferon Ribavirin Interferon Naive Subjects With Chronic Hepatitis C Genotype 1</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Key Interferon treatment naive subject chronic hepatitis C , HCV genotype 1 . Compensated liver disease Key Pregnant lactate female male pregnant partner . A positive test serum antibody human immunodeficiency virus ( HIV1 ) serum hepatitis B virus surface antigen ( HBsAg ) . A history moderate , severe uncontrolled psychiatric disease . A history immunologically mediate disease , seizure disorder , chronic cardiac disease , chronic pulmonary disease , hemoglobinopathy , coagulopathy , malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Hepatitis C</keyword>
</DOC>